Eversense 365 is the world’s first and only one year CGM, which was approved by the United States (US) Food and Drug Administration in September of 2024 and launched across the country in October of ...

Glucotrack, Inc.(“Glucotrack”, or the “Company”) (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, ...

Investing.com -- Glucotrack Inc. (NASDAQ:GCTK) stock surged 60% Thursday after the company announced that the U.S. Patent and ...

By Karen Roman GlucoTrack, Inc. (Nasdaq: GCTK) said the U.S. Patent and Trademark Office issued three patents for its continuous blood glucose monitoring platform as the company moves toward ...

Glucotrack, Inc.("Glucotrack", or the "Company") (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization ...

Following the update, Glucotrack stock traded over 12% higher in Thursday’s premarket. New Patents Strengthen IP The US ...

Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people ...

Glucotrack, Inc. (NASDAQ: GCTK) shares began Thursday substantially lower. The Rutherford, New Jersey-based company, a medical device concern focused on the design, development, and commercialization ...

Glucotrack (Nasdaq:GCTK) announced today that it received new U.S. patents for its continuous blood glucose monitoring (CBGM) ...

Senseonics (NYSE:SENS) announced today that its Eversense 365 continuous glucose monitor (CGM) system received CE mark ...

Fully automated, ultra-high-volume line providing sub-second cycle time, medical-grade precision, and scalable capacity ...

In December, the FDA granted breakthrough status for an implantable kidney replacement system for patients with end-stage kidney disease, according to a company press release.The Holly device by ...